share_log

Can-Fite Biopharma Shares Are Trading Lower. The Company Announced a Phase II Design Is Completed and Preparatory Work Is Undergoing for the Initiation of Clinical Study in the Rare Genetic Disease Lowe Syndrome.

Can-Fite Biopharma Shares Are Trading Lower. The Company Announced a Phase II Design Is Completed and Preparatory Work Is Undergoing for the Initiation of Clinical Study in the Rare Genetic Disease Lowe Syndrome.

CAN-Fite BioPharma的股票正在下跌。該公司宣佈第二階段設計已完成,正在進行爲啓動罕見遺傳疾病洛韋綜合症臨牀研究的準備工作。
Benzinga ·  03/19 15:38

Can-Fite Biopharma Shares Are Trading Lower. The Company Announced a Phase II Design Is Completed and Preparatory Work Is Undergoing for the Initiation of Clinical Study in the Rare Genetic Disease Lowe Syndrome.

CAN-Fite BioPharma的股票正在下跌。該公司宣佈第二階段設計已完成,正在進行爲啓動罕見遺傳疾病洛韋綜合症臨牀研究的準備工作。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 253

熱點推薦

搶先評論

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。